Buspirone/testosterone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Buspirone/testosterone
Combination of
Buspirone5-HT1A receptor agonist
TestosteroneAndrogen (AR agonist)
Clinical data
Other namesLybridos
Legal status
Legal status

Buspirone/testosterone (tentative brand name Lybridos) is a combination of buspirone, a 5-HT1A receptor partial agonist, α2-adrenergic receptor antagonist, and D2 autoreceptor antagonist,[1] and testosterone, an androgen or androgen receptor agonist, which is under development by the pharmaceutical company Emotional Brain for the treatment of female sexual dysfunction.[2][3] Both buspirone and testosterone have individually been found to be effective in the treatment of female sexual dysfunction in clinical studies, and so their combination could be anticipated to be even more effective.[4][5][6] As of January 2016, the combination is in phase II clinical trials, with a phase III trial being planned in the United States and Europe.[2]

See also[edit]

References[edit]

  1. ^ Loane C, Politis M (2012). "Buspirone: what is it all about?". Brain Res. 1461: 111–8. doi:10.1016/j.brainres.2012.04.032. PMID 22608068.
  2. ^ a b "Buspirone/Testosterone - Emotional Brain - AdisInsight".
  3. ^ Meston, Cindy M.; Stanton, Amelia M. (2017). "Treatment of Female Sexual Interest/Arousal Disorder". The Textbook of Clinical Sexual Medicine. pp. 165–168. doi:10.1007/978-3-319-52539-6_11. ISBN 978-3-319-52538-9.
  4. ^ Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R (2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clin. Proc. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID 27916394.
  5. ^ Nappi RE, Cucinella L (2015). "Advances in pharmacotherapy for treating female sexual dysfunction". Expert Opin Pharmacother. 16 (6): 875–87. doi:10.1517/14656566.2015.1020791. PMID 25732267.
  6. ^ Bolour SY, Braunstein GD (2005). "Pharmacologic treatment options for hypoactive sexual desire disorder". Womens Health (Lond). 1 (2): 263–77. doi:10.2217/17455057.1.2.263. PMID 19803843.

External links[edit]